APOA1 and Alzheimer disease: More recently, intravenous injection of reconstituted human HDL into AD mice was found to acutely reduce soluble amyloid levels in the brain[193], consistent with a previous rodent study in which oral administration of an apoA-I mimetic reduces Aβ burden in the brain[194].